Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Revenue of Ginkgo Bioworks Holdings, Inc. (DNA)
Revenue in 2023 (TTM): $251.46 M
According to Ginkgo Bioworks Holdings, Inc.'s latest financial reports the company's current revenue (TTM) is $251.46 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ginkgo Bioworks Holdings, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $251.46 M | $197.45 M | $-821,293,000 | $-892,940,000 | $-892,869,000 |
| 2022 | $477.71 M | $273.49 M | $-2,059,659,000 | $-2,121,399,000 | $-2,104,929,000 |
| 2021 | $313.84 M | $184.15 M | $-1,806,673,000 | $-1,838,122,000 | $-1,830,047,000 |
| 2020 | $76.66 M | $61.05 M | $-108,585,000 | $-124,834,000 | $-126,609,000 |
| 2019 | $54.18 M | $54.18 M | $-106,659,000 | $-119,835,000 | $-119,327,000 |
| 2001 | $98.29 M | $98.29 M | $-219,712,000 | $ | $ |